Clinical Impact of Enhanced Recovery After Esophagectomy in Patients With Esophageal Cancer
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: The enhanced recovery after surgery (ERAS) program is expected to improve perioperative outcomes in patients with esophageal cancer. However, how ERAS impacts the postoperative body composition and factors related to compliance rate of ERAS have not been fully investigated.
PATIENTS AND METHODS: The study included 252 consecutive patients with thoracic esophageal cancer who underwent minimally invasive esophagectomy. We compared the postoperative outcomes including body composition between the old perioperative program and the new one that aimed to shorten postoperative length of stay (LOS). Compliance-related clinical factors were also examined.
RESULTS: From 252 patients, 129 underwent the old program and 123 the new program. Postoperative LOS, postoperative complications, and hospital costs were reduced with the new program. Body weight loss was significantly improved with the new program at discharge and 3-months after esophagectomy (94.9% vs. 96.6%, p=0.013, 89.5% vs. 91.1%, p=0.028, respectively). Patients in the new program had better body composition at discharge than those in the old program [body fat mass (91.6% vs. 94.1%), lean body mass (95.2% vs. 97.2), and skeletal muscle mass (95.3% vs. 97.0%)]. Major reasons for incompliance were dysphagia, pneumonia, and anastomotic leakage. Multivariate analysis revealed that age ≥70 years at surgery and sex (male) were independent risk factors for incompliance with the postoperative program.
CONCLUSION: The new ERAS program aimed to shorten postoperative LOS had clinical benefits in body composition early after esophagectomy. Personalized ERAS programs based on age might lead to better postoperative outcomes because of low compliance rates for older patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Anticancer research - 43(2023), 9 vom: 30. Sept., Seite 4197-4205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sugase, Takahito [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Body composition |
|---|
| Anmerkungen: |
Date Completed 01.09.2023 Date Revised 01.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/anticanres.16611 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361461569 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361461569 | ||
| 003 | DE-627 | ||
| 005 | 20231226085204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/anticanres.16611 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361461569 | ||
| 035 | |a (NLM)37648293 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sugase, Takahito |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Impact of Enhanced Recovery After Esophagectomy in Patients With Esophageal Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.2023 | ||
| 500 | |a Date Revised 01.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: The enhanced recovery after surgery (ERAS) program is expected to improve perioperative outcomes in patients with esophageal cancer. However, how ERAS impacts the postoperative body composition and factors related to compliance rate of ERAS have not been fully investigated | ||
| 520 | |a PATIENTS AND METHODS: The study included 252 consecutive patients with thoracic esophageal cancer who underwent minimally invasive esophagectomy. We compared the postoperative outcomes including body composition between the old perioperative program and the new one that aimed to shorten postoperative length of stay (LOS). Compliance-related clinical factors were also examined | ||
| 520 | |a RESULTS: From 252 patients, 129 underwent the old program and 123 the new program. Postoperative LOS, postoperative complications, and hospital costs were reduced with the new program. Body weight loss was significantly improved with the new program at discharge and 3-months after esophagectomy (94.9% vs. 96.6%, p=0.013, 89.5% vs. 91.1%, p=0.028, respectively). Patients in the new program had better body composition at discharge than those in the old program [body fat mass (91.6% vs. 94.1%), lean body mass (95.2% vs. 97.2), and skeletal muscle mass (95.3% vs. 97.0%)]. Major reasons for incompliance were dysphagia, pneumonia, and anastomotic leakage. Multivariate analysis revealed that age ≥70 years at surgery and sex (male) were independent risk factors for incompliance with the postoperative program | ||
| 520 | |a CONCLUSION: The new ERAS program aimed to shorten postoperative LOS had clinical benefits in body composition early after esophagectomy. Personalized ERAS programs based on age might lead to better postoperative outcomes because of low compliance rates for older patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ERAS | |
| 650 | 4 | |a Enhanced recovery after surgery | |
| 650 | 4 | |a body composition | |
| 650 | 4 | |a length of stay | |
| 650 | 4 | |a postoperative body weight loss | |
| 700 | 1 | |a Kanemura, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Takeoka, Tomohira |e verfasserin |4 aut | |
| 700 | 1 | |a Urakawa, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Sugimura, Keijiro |e verfasserin |4 aut | |
| 700 | 1 | |a Masuike, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Shinno, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Hisashi |e verfasserin |4 aut | |
| 700 | 1 | |a Omori, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kitakaze, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Mukai, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sueda, Toshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Akita, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yasui, Masayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyata, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 43(2023), 9 vom: 30. Sept., Seite 4197-4205 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:9 |g day:30 |g month:09 |g pages:4197-4205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/anticanres.16611 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 9 |b 30 |c 09 |h 4197-4205 | ||